Nucleix

NucleixNucleix
Nucleix

Nucleix

Nucleix is a liquid biopsy company developing early cancer detection solutions using methylation analysis.

DR 382008Active74Rehovot, Israel
Rate

About

Nucleix is a liquid biopsy company focused on revolutionizing cancer treatment through earlier disease detection. They leverage NGS-based and PCR-based technology to identify methylation changes, offering a pioneering testing approach that aims to detect cancer at a stage where intervention can have the greatest impact for patients.
Frequently asked

What does Nucleix do?

Nucleix is a liquid biopsy company focused on revolutionizing cancer treatment through earlier disease detection. They leverage NGS-based and PCR-based technology to identify methylation changes, offering a pioneering testing approach that aims to detect cancer at a stage where intervention can have the greatest impact for patients.

What is Nucleix's revenue?

StartupHub estimates Nucleix's annual revenue at $13.9M (range $8.7M to $20.5M, 66% confidence), based on comparable companies in the sector.

What is Nucleix's valuation?

StartupHub estimates Nucleix's effective valuation at $420.2M (range $255.0M to $612.0M, 10% confidence), based on comparable companies in the sector.

How much funding has Nucleix raised?

Nucleix has raised a total of $102M in funding. The most recent round on record is Funding Round.

Where is Nucleix headquartered?

Nucleix is headquartered in Rehovot, Israel.

When was Nucleix founded?

Nucleix was founded in 2008.

What industry does Nucleix operate in?

Nucleix operates in Healthcare, Lung, Bladder, Cancer, Diagnostics, Biomarkers.

How many employees does Nucleix have?

Nucleix has approximately 74 people on record.

HEADCOUNT
74
DOMAIN RATING
38
Comments
(6)
6 positive0 mixed0 negative
Reddit
r/LungCancerSupportu/WalkingHorseApr 5, 2024Positive💎

Nucleix Demonstrates Potential of its PCR EpiCheck® Assay to Accurately Differentiate Between Small Cell Lung Cancer (SCLC) Subtypes.

View on Reddit
Reddit
r/nsclcu/montaukwhalerApr 10, 2021Positive

Armed With $55M in New Funding, Nucleix to Further Invest in Early-Stage Lung Cancer Dx.

View on Reddit
Reddit
r/prnewswireu/prnewswireadminMar 26, 2018Positive

D'après des experts européens de premier plan dans le domaine du cancer de la vessie, le test d'urine Bladder EpiCheck de Nucleix peut réduire les procédures invasives.

View on Reddit
Reddit
r/prnewswireu/prnewswireadminMar 26, 2018Positive

Führende europäische Blasenkrebsexperten: der Urintest Bladder EpiCheck von Nucleix kann invasive Verfahren reduzieren.

View on Reddit
Reddit
r/prnewswireu/prnewswireadminMar 26, 2018Positive

I principali esperti europei del cancro alla vescica dichiarano: il test delle urine Bladder EpiCheck di Nucleix può ridurre le procedure invasive.

View on Reddit
Reddit
r/prnewswireu/prnewswireadminMar 26, 2018Positive

El Nucleix Bladder EpiCheck Urine Test puede reducir los procedimientos invasivos.

View on Reddit

Some comments are pulled from public discussions around the web (look for the source icon). Quotes are excerpts; click through to read the full thread.